Kyverna Therapeutics (NASDAQ: KYTX) will present interim Phase 2 data from its KYV-101 therapy trial in myasthenia gravis at the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE